Expression, purification, and molecular analysis of the Necator americanus glutathione S-transferase 1 (Na-GST-1): A production process developed for a lead candidate recombinant hookworm vaccine antigen

► We describe the expression and purification of Na-GST-1 in the yeast Pichia pastoris. ► Recovery rates obtained were suitable for material for Phase 1 trial. ► A human hookworm vaccine is under development. The enzyme Necator americanus glutathione S-transferase 1 (Na-GST-1) belongs to a unique Nu...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Protein expression and purification 2012-06, Vol.83 (2), p.145-151
Hauptverfasser: Goud, Gaddam Narsa, Deumic, Vehid, Gupta, Richi, Brelsford, Jill, Zhan, Bin, Gillespie, Portia, Plieskatt, Jordan L., Tsao, Eric I., Hotez, Peter J., Bottazzi, Maria Elena
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:► We describe the expression and purification of Na-GST-1 in the yeast Pichia pastoris. ► Recovery rates obtained were suitable for material for Phase 1 trial. ► A human hookworm vaccine is under development. The enzyme Necator americanus glutathione S-transferase 1 (Na-GST-1) belongs to a unique Nu class of GSTs and is a lead candidate antigen in a bivalent human hookworm vaccine. Here we describe the expression of Na-GST-1 in the yeast Pichia pastoris at the 20L manufacturing scale and its purification process performed by three chromatographic steps, comprised of a Q Sepharose XL anion exchange column, followed by a Butyl Sepharose HP hydrophobic affinity column and a Superdex 75 size-exclusion column. Approximately 1.5g of recombinant protein was recovered at an overall process yield of 51%, with a purity grade of 98% and the absence of detectable host cell protein. By mass spectrometry the recombinant protein exhibits a mass of 23,676Da, which closely matches the predicted molecular mass of the protein. The expression and purification methods described here are suitable for further scale-up product development and for its use to design formulation processes suitable to generate a vaccine for clinical testing.
ISSN:1046-5928
1096-0279
DOI:10.1016/j.pep.2012.03.013